Opthea Ltd

OPT

Company Profile

  • Business description

    Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.

  • Contact

    C/ Prime Company Compliance
    505 Little Collins Street, Level 9
    MelbourneVIC3000
    AUS

    T: +61 398260399

    https://www.opthea.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    10

Stocks News & Analysis

stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.
stocks

Is there a long-term buying opportunity in luxury stocks?

Our analysts think the recent wobble in revenue growth is cyclical, not structural.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,141.6018.700.20%
CAC 407,830.1123.48-0.30%
DAX 4023,527.05112.36-0.48%
Dow JONES (US)46,381.5466.270.14%
FTSE 1009,226.6810.010.11%
HKSE26,080.30263.84-1.00%
NASDAQ22,788.98157.500.70%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,136.545.00-0.04%
S&P 5006,693.7529.390.44%
S&P/ASX 2008,850.6019.000.22%
SSE Composite Index3,788.0540.53-1.06%

Market Movers